

# Warts Treatment Pipeline Review H2 2016

*Warts - Pipeline Review, H2 2016*

PUNE, INDIA, August 30, 2016

/EINPresswire.com/ -- Summary

'[Warts](#) - Pipeline Review, H2 2016', provides an overview of the Warts pipeline landscape. The report provides comprehensive information on the therapeutics under development for Warts, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Warts and features dormant and discontinued projects.



Complete report details @ <https://www.wiseguyreports.com/reports/619289-warts-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/619289-warts->

## Scope

- The report provides a snapshot of the global therapeutic landscape of Warts
- The report reviews pipeline therapeutics for Warts by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Warts therapeutics and enlists all their major and minor projects
- The report assesses Warts therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Warts

## Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Warts
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Warts pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/619289-warts-pipeline-review-h2-2016>

## Key points in table of content

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage	8
Warts Overview	9
Therapeutics Development	10
Pipeline Products for Warts - Overview	10
Warts - Therapeutics under Development by Companies	11
Warts - Pipeline Products Glance	13
Clinical Stage Products	13
Early Stage Products	14
Warts - Products under Development by Companies	15
Warts - Companies Involved in Therapeutics Development	17
3M Drug Delivery Systems	17
Aclaris Therapeutics, Inc.	18
Agilvax, Inc.	19
Aviragen Therapeutics, Inc.	20
Biogenomics Limited	21
BioMAS Ltd.	22
Cytovation AS	23
Foamix Pharmaceuticals Ltd.	24
G&E Herbal Biotechnology Co., Ltd.	25
Laboratories Ojer Pharma S.L.	26
LEO Pharma A/S	27
Nielsen Biosciences, Inc.	28
Novan, Inc.	29
Novartis AG	30
Promius Pharma, LLC	31
RXi Pharmaceuticals Corporation	32
Tamir Biotechnology, Inc.	33
Verrica Pharmaceuticals Inc.	34
Zydus Cadila Healthcare Limited	35
Warts - Therapeutics Assessment	36
Assessment by Monotherapy Products	36
Assessment by Combination Products	37
Assessment by Target	38
Assessment by Mechanism of Action	40
Assessment by Route of Administration	42
Assessment by Molecule Type	44
Drug Profiles	46
(cervical cancer + genital warts) vaccine - Drug Profile	46
Product Description	46
Mechanism Of Action	46
R&D Progress	46
(digoxin + furosemide) - Drug Profile	47
Product Description	47

Mechanism Of Action 47  
R&D Progress 47  
854-A - Drug Profile 48  
Product Description 48  
Mechanism Of Action 48  
R&D Progress 48  
AS-101 - Drug Profile 49  
Product Description 49  
Mechanism Of Action 49  
R&D Progress 49  
AX-03 - Drug Profile 51  
Product Description 51  
Mechanism Of Action 51  
R&D Progress 51  
BTA-074 - Drug Profile 52  
Product Description 52  
Mechanism Of Action 52  
R&D Progress 52  
Candida Albicans Antigen - Drug Profile 54  
Product Description 54  
Mechanism Of Action 54  
R&D Progress 54  
CyPep-1 - Drug Profile 55  
Product Description 55  
Mechanism Of Action 55  
R&D Progress 55  
DFD-05 - Drug Profile 56  
Product Description 56  
Mechanism Of Action 56  
R&D Progress 56  
diphencyprone - Drug Profile 57  
Product Description 57  
Mechanism Of Action 57  
R&D Progress 57  
FIT-039 - Drug Profile 59  
Product Description 59  
Mechanism Of Action 59  
R&D Progress 59  
human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile 60  
Product Description 60  
Mechanism Of Action 60  
R&D Progress 60  
hydrogen peroxide - Drug Profile 61

Product Description 61  
Mechanism Of Action 61  
R&D Progress 61  
imiquimod - Drug Profile 63  
Product Description 63  
Mechanism Of Action 63  
R&D Progress 63  
imiquimod SR - Drug Profile 64  
Product Description 64  
Mechanism Of Action 64  
R&D Progress 64  
ingenol mebutate - Drug Profile 65  
Product Description 65  
Mechanism Of Action 65

Buy this report @ [https://www.wiseguyreports.com/checkout?currency=one\\_user-USD&report\\_id=619289](https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=619289)

Norah Trent  
wiseguyreports  
+1 646 845 9349 / +44 208 133 9349  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/342365405>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.